Relmada Therapeutics is a clinical-stage firm that develops some of the best novel therapies for treating chronic pain. Recently, the institution announced that U.S. District Court for District of Nevada had given an associate injunction and temporary restraining order that would enjoin a company known as Laidlaw and Company and its principles from continuing to disseminate any misleading proxy materials or false information. The principles of the company are James Ahern and Matthew Eitner.
The U.S District Court decided to issue the order after Relmada filed a case in court against Laidlaw and Messrs. The two principles of the company received the order because of disseminating material that is believed to be false and some misleading information.
Laidlaw is a well-known investment brokerage company. In the past, the company was operating as the investment banker to Relmada Therapeutics. This is not the first time the brokerage company has found itself in trouble. In the past, the institution, together with its principle has been caught violating the financial regulations in the country. This always ends up to many customer complaints, monetary penalties and regulatory sanctions. Most of the cases against this case end up in court, ruining the reputation of the company.
The Chief Executive Officer of Relmada Therapeutics, Sergio Treaversa says that he is happy that the court realized the importance of the request issued by his company and later issuing the order. The company would have preferred mostly focus on its main objective of producing products. They believe that it would not be good for Laidlaw to control it.
Laidlaw & Company is a popular full-service investment bank and a respected brokerage company that offers consumers personalized investment advice.